MODELING DEPRESSION


Cite item

Full Text

Abstract

The article provides an overview of common methods for modeling the depressive behavior of laboratory rats and mice. Information is presented from databases NCBI (National Center for Biotechnology Information), eLibrary, CyberLeninka. The classification of models is presented, the methods are compared by criteria of validity. The positive and negative sides of each of the methods of modeling depression are considered.

About the authors

Denis A. Borozdenko

N.I. Pirigov Russian National Research Medical University

Email: borozdenko@phystech.edu
assistant of the Department of pharmacology, N.I. Pirogov Russian National Research Medical University, Moscow, 117997, Russian Federation 117997, Moscow, Russian Federation

S. S Khovanova

N.I. Pirigov Russian National Research Medical University

117997, Moscow, Russian Federation

N. M Kiseleva

N.I. Pirigov Russian National Research Medical University

117997, Moscow, Russian Federation

Vad. V Negrebetsky

N.I. Pirigov Russian National Research Medical University

117997, Moscow, Russian Federation

References

  1. World Health Organization Depression and Other Common Mental Disorders: Global Health Estimates. World Health Organization 2017. Available at: https://apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf;jsessionid=FB3E403FCB4E2C4C7001C450A1CB23B5?sequence=1.
  2. Sullivan P. F., Neale M.C., Kendler K.S. Genetic Epidemiology of Major Depression: Review and Meta-Analysis. American Journal of Psychiatry. 2000; 157(10): 1552-62.
  3. McGuffin P., Cohen S., Knight J. Homing in on Depression Genes. American Journal of Psychiatry. 2007; 164(2): 195-7.
  4. Menke A., Klengel T., Binder B.E. Epigenetics, Depression and Antidepressant Treatment. Current.Pharmaceutical Design. 2012; 18(36): 5879-89.
  5. Deverteuil R.L., Lehmann H.E. Therapeutic trial of iproniazid (marsilid) in depressed and apathetic patients. Can Med Assoc J. 1958; 78: 131-3.
  6. Kraft J.B., Slager S.L., McGrath P.J., Hamilton S.P. Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry. 2005; 58: 374-81.
  7. Hu X.Z., Lipsky R.H., Zhu G., Akhtar L.A., Taubman J., Greenberg B.D. et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet. 2006; 78: 815-26.
  8. Kuhn R. The treatment of depressive states with G 22355 (imipramine hydrochloride). Am J Psychiatry. 1958; 115: 459-64.
  9. Schildkraut J.J., Kety S.S. Biogenic amines and emotion. Science. 1967; 156: 21-37.
  10. Bao A.M., Meynen G., Swaab D.F. The stress system in depression and neurodegeneration: focus on the human hypothalamus. Brain Res Rev. 2008; 57: 531-53.
  11. Парфенов В.А. Постинсультная депрессия: распространенность, патогенез, диагностика и лечение. Неврология, нейропсихиатрия, психосоматика. 2012;4(4):84-88.
  12. Образовательная программа по депрессивным расстройствам. Всемирная психиатрическая ассоциация расстройствам Mario Maj, Norman Sartorius, Allan Tasman, Oye Gureje, пер. на рус. яз. вып. в Московском НИИ психиатрии под ред. проф. Краснова В.Н., 2010 Available at: http://bekhterev.ru/content/43/OT1.pdf.
  13. Thase ME. Depression and sleep: pathophysiology and treatment. Dialogues Clin Neurosci. 2006; 8(2): 217-226.
  14. Kumar A., Newberg A., Alavi A., Berlin J., Smith R., Reivich M. Regional cerebral glucose metabolism in late-life depression and Alzheimer disease: a preliminary positron emission tomography study. Proc Natl Acad Sci U S A. 1993; 90(15): 7019-23.
  15. Бауэр М., Пфенниг А., Северус Э., Вайбрау П.С., Ангст Ж., Мюллер Х.-Ю. Клинические рекомендации Всемирной федерации обществ биологической психиатрии по биологической терапии униполярных депрессивных расстройств. Современная терапия психических расстройств. 2016;1: 31-48
  16. The National Institute for Health and Care Excellence (NICE) Depression in adults: recognition and management. Clinical guideline [CG90]. NICE. 2018. Available at: https://www.nice.org.uk/guidance/cg90
  17. Seltzer V., Tonge S.R. Methylamphetamine withdrawal as a model for the depressive state: antagonism of post-amphetamine depression by imipramine. J Pharm Pharmacol. 1975; 27 Suppl 2.
  18. Григорьян Г.А., Гуляева Н.В. Моделирование депрессии на животных: поведение как основа методологии, критериев оценки и классификации. Журнал высшей нервной деятельности. 2015; 65 (6): 1-18
  19. Willner P. The validity of animal models of depression. Psychopharmacology. 1984; 83(1): 1-16.
  20. Dedic N., Walser S.M., Jan M. Deussing J.M. Mouse Models of Depression. In: Dr. Toru Uehara Chapter, ed. Psychiatric Disorders - Trends and Developments. InTech. 2011: 185-222.
  21. Калуев А.В. Экспериментальное моделирование тревожности и депрессии. Психофармакология. и биология. наркология. 2004; 4 (2-3): 663-70
  22. Willner, P., Mitchell, P. J. The validity of animal models of predisposition to depression. Behavioural Pharmacology. 2002; 13(3): 169-88
  23. Яузина Н.А., Комлева Ю.К., Салмина А.Б., Петрова М.М., Морозова Г.А., Малиновская Н.А., Герцог Г.Е. Современные экспериментальные модели депрессии. Биомедицина. 2013; 1: 61-77
  24. Demin Ma. L., Kolesnikov K.A., Kharsko T.O., Zhu S.L., Yuan X., Kalueff X. Animal inflammation-based models of depression and their application to drug discovery. Expert Opinion on Drug Discovery. 2017; 12(10): 995-1009.
  25. Caldarone B. J., Zachariou V., King S. L. Rodent models of treatment-resistant depression. European Journal of Pharmacology. 2015; 753: 51-65.
  26. Hennessy M.B., Deak T., SchimlWebb P.A. Early attachment-figure separation and increased risk for laterdepression: potential mediation by proinflammatoryprocesses. Neurosci. Biobehav. Rev. 2010; 34(6): 782-90.
  27. Pournajafi-Nazarloo H., Partoo L., Yee J., Stevenson J., Sanzenbacher L., Kenkel W., Mohsenpour S.R.,Hashimoto K., Carter C.S. Effects of social isolation on mRNA expression for corticotrophin-releasing hormone receptors in prairie voles. Psychoneuroendocrinology. 2011; 36(6): 780-9.
  28. Кудрявцева Н.Н., Августинович Д.Ф., Коваленко И.Л., Бондарь Н.П. Развитие ангедонии под влиянием негативного опыта социальных взаимодействий у самцов мышей. Российский физиологический журнал им И.М. Сеченова. 2006; 92(3): 351-61
  29. Lanfumey L., Mannoury La Cour C., Froger N., Hamon M. 5-HT-HPA interactions in two models of transgenic mice relevant to major depression. Neurochem Res. 2000; 25: 1199-206.
  30. Song Cai Leonard, Brian E. The olfactory bulbectomised rat as a model of depression. Neuroscience & Biobehavioral Reviews. 2005; 29 (4-5): 627-47.
  31. Wang Y., Cui X.L., Liu Y.F., Gao F., Wei D., Li X.W. et al. LPS inhibits the effects of fluoxetine on depression-like behavior and hippocampal neurogenesis in rats. Progress in neuro-psychopharmacology & biological psychiatry. 2011; 35 (8): 1831-5.
  32. Sammut S., Bethus I., Goodall G. et al. Antidepressant reversal of interferon-alpha-induced anhedonia. Physiol Behav. 2002; 75: 765-72.
  33. Gourley S.L., Kiraly D.D., Howell J.L., Olausson P., Taylor J.R. Acute Hippocampal Brain-Derived Neurotrophic Factor Restores Motivational and Forced Swim Performance After Corticosterone. Biological Psychiatry. 2008; 64(10): 884-90.
  34. O’Neil Michael F., Moore Nicholas A. Animal models of depression: are there any? Human Psychopharmacology: Clinical and Experimental. 2003; 18 (4): 239-54.
  35. Аляутдин Р.Н., Романов Б.К., Гусейнов М.Д. и др. Экспериментальная скрининговая оценка стресспротекторного действия фитопрепаратов. Российский медицинский журнал. 2008; 3: 29-33
  36. Durgam Robert C. Rodent models of depression: learned helplessness using a triadic design in rats. Current Protocols in Neuroscience. 2001; 8.10B.1-8.10B.12.
  37. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berl). 1997; 134(4): 319-29.
  38. Su K., Lai H.C., Peng C.Y., Su W.P., Chang J.P., Pariante C.M. Interferon-alpha-induced depression: Comparisons between early- and late-onset subgroups and with patients with major depressive disorder. Brain Behav Immun. 2019; May 4. pii: S0889-1591(19)30035-2. doi: 10.1016/j.bbi.2019.04.032. [Epub ahead of print].

Copyright (c) 2019 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies